Tests for interaction terms for FABP‐4 with tumor subsite were significant for CRC‐specific and all‐cause mortality (p = .02 for both outcomes) (Figure 2): there were positive associations between FABP‐4 concentrations and CRC‐specific mortality (HR per SD = 1.15; 95% CI: 1.05–1.26) as well as all‐cause mortality (HR per SD = 1.16; 95% CI: 1.06–1.26) in individuals with colon cancer but not in those with rectal cancer. This evidence concerns the gene FABP4 and rectal cancer.